Mabpharm Sets March 26 Board Meeting to Approve 2025 Annual Results

Mabpharm Limited ( (HK:2181) ) has provided an announcement.

Mabpharm Limited has scheduled a board meeting for March 26, 2026, to review and approve the annual results for the year ended December 31, 2025. The board will also consider the publication of these results and address other corporate matters at the same meeting, signaling the upcoming disclosure of the company’s financial and operational performance to the market.

The announcement formally confirms the timetable for the company’s year-end reporting process, which is a key event for shareholders and other stakeholders tracking Mabpharm’s progress. With the full board structure disclosed, the notice also underscores the governance framework overseeing these decisions and the company’s compliance with Hong Kong listing requirements.

The most recent analyst rating on (HK:2181) stock is a Hold with a HK$0.51 price target. To see the full list of analyst forecasts on Mabpharm Limited stock, see the HK:2181 Stock Forecast page.

More about Mabpharm Limited

Mabpharm Limited is a biopharmaceutical company incorporated in the Cayman Islands and listed on the Hong Kong Stock Exchange. The company focuses on developing and commercializing pharmaceutical products, operating through a board comprising executive, non-executive and independent non-executive directors with oversight of its strategic and financial activities.

Average Trading Volume: 364,914

Technical Sentiment Signal: Sell

Current Market Cap: HK$2.1B

For an in-depth examination of 2181 stock, go to TipRanks’ Overview page.